Marc Oczachowski, Chief Executive Officer of EDAP TMS, commented, "Our sales and marketing teams remain very much committed to implementing focused marketing initiatives and in promoting our technologies. We will continue to actively work with the Urology community to position HIFU as the preferred solution to address prostate cancer and particularly its ability to focally approach localized prostate cancer tumors."
About EDAP TMS SA
EDAP TMS SA develops and markets Ablatherm, the most advanced and clinically proven choice for high-intensity focused ultrasound (HIFU) treatment of localized prostate cancer. HIFU treatment is shown to be a minimally invasive and effective treatment option with a low occurrence of side effects. Ablatherm-HIFU is generally recommended for patients with localized prostate cancer (stages T1-T2) who are not candidates for surgery or who prefer an alternative option, or for patients who failed radiotherapy treatment. Approved in Europe as a treatment for prostate cancer, Ablatherm-HIFU (High Intensity Focused Ultrasound) is currently undergoing evaluation in a multicenter U.S. Phase II/III clinical trial under an Investigational Device Exemption granted by the FDA. The Company also is developing this technology for the potential treatment of certain other types of tumors. EDAP TMS SA also produces and commercializes medical equipment for treatment of urinary tract stones using extra-corporeal shockwave lithotripsy (ESWL). For more information on the company, please visit
CONTACT: EDAP TMS SA
Investor Relations/Legal Affairs
+33 4 72 15 31 72
The Ruth Group